Brainspotting for Trauma-Related Symptoms: A Proposed Mechanistic Model and Appraisal of Clinical Evidence

Abstract

Background. Brainspotting (BSP) is a trauma-oriented psychotherapy in which a therapist helps a client locate and sustain attention on a visual-field position associated with trauma-related somatic activation. Its proposed neurobiological explanation is prominent in clinical descriptions, but its empirical status needs to be separated from the clinical-outcome question.[1, 2]

Objective. To describe the BSP procedure, appraise the available studies of trauma-related outcomes, and state a falsifiable account of how BSP might operate.

Evidence identification. This narrative evidence review searched academic sources using terms for Brainspotting, trauma, PTSD, treatment outcomes, mechanisms, and systematic reviews; it also checked major PTSD treatment guidance. It is not a registered systematic review. The outcome papers identified include preliminary uncontrolled cohorts, comparator studies of distressing memories, and a small comparative PTSD study.[3–5]

Results. Small uncontrolled PTSD cohorts, a nonclinical experiment with an active control, and a comparative clinical study all report reductions in trauma-related symptoms or memory distress after BSP. The clinical PTSD literature is nevertheless small, heterogeneous, and dominated by nonrandomized, self-report, brief-treatment designs. The available neuroimaging work consists of single-case pre–post studies and cannot establish BSP-specific neural mechanisms.[4–9]

Conclusion. BSP is a plausible candidate trauma-focused intervention with preliminary signals of benefit, not an established first-line PTSD treatment. Its characteristic claim—that a specific gaze position has a causal, reproducible role in symptom change—remains untested. A decisive next study would use a preregistered, adequately powered randomized design comparing therapist-delivered BSP with matched trauma-focused attention at a sham visual position and with an established trauma therapy.[4, 6, 9, 10]

Keywords: Brainspotting; post-traumatic stress disorder; trauma psychotherapy; visual attention; somatic symptoms; mechanism; clinical trial

Introduction

Brainspotting is presented as a psychotherapy that identifies a visual-field location at which recounting or contacting a traumatic experience is accompanied by increased bodily activation. The client then maintains attention at that location while observing internal experience, supported by a therapist’s attunement. The foundational mechanistic paper describes this as a clinical observation and explicitly frames its neural account as a set of testable hypotheses, rather than demonstrated neurobiology.[1]

The distinction matters. A patient may improve during BSP because of trauma-memory activation, sustained attention, expectancy, therapeutic alliance, emotional exposure, interoceptive monitoring, spontaneous recovery, or a combination of these. Improvement alone does not show that the proposed “brainspot,” a midbrain pathway, or a specific eye position caused the change; the mechanistic accounts themselves are framed as hypotheses.[1, 2] The appropriate scientific question is therefore twofold: does BSP improve clinically important trauma outcomes, and does its gaze-position procedure contribute incrementally beyond credible alternatives?

What happens in Brainspotting?

In BSP, the therapist and client identify a position in the client’s visual field that appears to correspond with heightened trauma-linked bodily or emotional activation; the client holds attention at that position while processing the experience. The early theoretical account proposes that sustained attention on this “brainspot,” within an attuned therapeutic relationship, permits traumatic activation to be processed.[1] The later account proposes that excessively high arousal interrupts full orientation to an aversive memory, and that mindful attention may enable coherent thalamocortical processing and subsequent reconsolidation with less distress.[2]

This description supports a clinically intelligible, but unproven, process model:

1. a trauma reminder evokes bodily and affective activation;
2. a selected visual position becomes an attentional anchor;
3. sustained, tolerable contact with the memory and its sensations occurs in a regulated therapeutic relationship;
4. the client experiences new affective, cognitive, and somatic responses; and
5. distress decreases on later recall.[1, 2]

The first three steps describe the intervention; the claim that a particular visual position has privileged neural access is a mechanistic hypothesis requiring direct experimental support.

Clinical evidence for trauma outcomes

The evidence base contains several positive signals, but no single study is sufficient to establish efficacy for PTSD.

An early uncontrolled study evaluated 22 BSP-treated clients in Germany and the United States. It reported questionnaire-based reductions in PTSD symptoms and other impairments over three sessions, using client and therapist ratings.[3] Because there was no concurrent comparator, the study cannot distinguish a BSP-specific effect from nonspecific therapy effects, regression to the mean, expectancy, or natural symptom change.

A 2017 comparative study enrolled 76 adults affected by traumatic events; 53 received BSP and 23 received EMDR, each delivered as three 60-minute sessions under a standard protocol. PTSD, depression, and anxiety were measured before and after treatment and at six months. Both groups improved in self-reported PTSD symptoms, with large within-group pre–post changes reported for BSP and EMDR.[4] This is the most clinically relevant comparative signal found in this review, but the unequal group sizes, very brief treatment exposure, and reliance on self-reported primary outcomes leave the comparative efficacy question unresolved.

A 2022 one-group, three-time-point study involved 13 women in residential care with severe interpersonal-trauma histories and elevated PTSD symptoms for at least two years. After three manual-guided BSP sessions, clinician-administered and self-report PTSD measures improved, and the report describes large within-person effects maintained at a two-week follow-up.[6] The severity of the enrolled population and use of CAPS-5 are strengths; the absence of randomization, a control condition, and a longer follow-up prevents causal attribution to BSP.

The more controlled experimental evidence concerns distressing memories in nonclinical participants, not diagnosed PTSD. In a within-subject pilot, BSP was compared with body-scan meditation; after approximately 40 minutes, BSP was associated with lower memory-related distress and higher heart-rate-variability parameters than baseline.[7] A related within-subject study in 40 psychologists or physicians compared single sessions of EMDR, BSP, body-scan meditation, and book reading. BSP and EMDR produced lower post-session and follow-up distress ratings than body scan and reading, and both reduced the duration needed to recount the memory.[5] These studies suggest that BSP can alter acute distress in selected healthy samples; they do not establish treatment of PTSD, durability, or superiority to established trauma therapies.

Neurobiological evidence: promising observations, not confirmation

The BSP-specific neurobiological account has not yet been validated by a controlled mechanistic program. A PET pre–post report involved one participant with PTSD and one healthy control after 30 online BSP sessions; symptoms decreased, whereas PET findings were described as variable.[8] A later online BSP study similarly reported symptom and spectroscopy changes after 15 sessions in a single trauma survivor, while acknowledging that the one-case, nonrandomized design and self-report dependence limit generalizability.[9] Neither study can isolate BSP from repeated therapeutic contact, time, measurement variation, or other factors; neither establishes that a brainspot recruits a named circuit.

The current evidence therefore supports a careful formulation: changes in symptoms and physiological or imaging measures have been observed after BSP in preliminary studies, but no study found here demonstrates a BSP-specific neural mechanism. The original midbrain, pulvinar, thalamocortical, and reconsolidation accounts should be cited as hypotheses.[1, 2]

A testable thesis: the gaze-anchored, regulated reactivation model

We propose the following thesis for empirical testing:

In people with PTSD, a visually anchored point that is individually linked to trauma-cue arousal facilitates sustained, tolerable reactivation of the trauma memory; when delivered in a regulated therapeutic relationship, this produces greater reduction in conditioned distress and avoidance than identical trauma-focused attention at a non-linked visual point.[1, 2]

This thesis does not require assuming that eye position directly accesses a stored memory or that BSP uniquely engages a particular midbrain circuit. It makes four separable predictions:

• Specificity of the anchor. A participant-selected brainspot should outperform a randomly assigned or deliberately non-linked gaze position when therapist contact, exposure time, expectancy, and trauma-memory target are matched.
• Process engagement. During active processing, the selected brainspot should produce measurable—but tolerable—changes in autonomic arousal, attention, and trauma-memory activation relative to sham position; an increase in arousal alone is not evidence of benefit.
• Clinical mediation. Reductions in avoidance, reactivity to trauma cues, and PTSD severity should be mediated by within-session change in trauma-memory distress rather than by nonspecific expectancy alone.
• Durability and generalization. Any advantage should persist at least three to six months and generalize to clinician-rated PTSD severity, functioning, and trauma-cue tasks—not only immediate subjective distress. These predictions address the short treatment and follow-up windows in the available studies.[4–6]

The model can fail in informative ways. If matched sham gaze positions work equally well, the therapeutic ingredient is likely sustained trauma-focused attention or alliance rather than visual-position specificity. If BSP improves symptoms without demonstrating the predicted physiological or behavioral changes, its clinical benefit may still be real, but the proposed mechanism should be revised. If it does not outperform a credible control, the field should not retain a claim of distinctive neurobiological access. This is necessary because the named neurobiological pathways remain author-proposed hypotheses.[1, 2]

Study needed to test the thesis

A definitive trial should recruit adults with clinician-confirmed PTSD, preregister primary and mechanistic outcomes, and randomize participants to: (a) BSP at an individually identified brainspot; (b) matched therapist-delivered trauma processing at a non-linked, sham visual location; and (c) an established trauma-focused treatment delivered at an adequate dose. Therapist allegiance, treatment credibility, session number, attention, and homework should be balanced as far as feasible. Blinded evaluators should assess CAPS-5, functioning, depression, dissociation, adverse symptom exacerbation, and treatment retention at post-treatment and at 3-, 6-, and 12-month follow-up. This design directly addresses the absence of randomization and small samples in the preliminary PTSD studies.[6, 9]

Mechanistic measures should include a preregistered trauma-cue task, continuous autonomic measures, and—if feasible—functional neuroimaging or electrophysiology during standardized memory activation. Neural measures should test a priori contrasts between the selected and sham visual positions; descriptive pre–post regional changes cannot identify a gaze-specific mechanism. The trial should also capture adverse events and symptom worsening, which are essential for assessing any trauma therapy. This moves beyond the available pre–post PET and spectroscopy case reports.[8, 9]

Clinical positioning

BSP should currently be described as an emerging or adjunctive approach rather than a replacement for established PTSD care. For adults with PTSD, NICE recommends individual trauma-focused cognitive behavioral therapies and also recommends EMDR in specified adult presentations; its listed interventions do not include BSP.[10] This absence is consistent with an evidence base that is too small for guideline-level endorsement, not proof that BSP is ineffective.

A defensible clinical statement is therefore narrower than many promotional claims: BSP has preliminary supportive findings for reducing trauma-related symptoms and distress, including small clinical cohorts and nonclinical comparator studies, but the literature does not yet demonstrate robust efficacy, comparative effectiveness, safety, or a distinctive neural mechanism in PTSD.[4–6, 9]

Conclusion

BSP offers a coherent therapeutic procedure—gaze-anchored attention to trauma-linked experience within an attuned relationship—and early studies report improvement in PTSD symptoms and distressing-memory outcomes.[4–6] The central evidentiary gap is not whether symptom change has ever been observed; it has. The gap is whether BSP’s visual-position procedure adds a reproducible, clinically meaningful benefit over matched trauma processing and established trauma therapies. Until randomized, adequately controlled trials answer that question, claims that BSP “works by accessing the midbrain” should be treated as a testable thesis, not an established explanation.[1, 2]

Declarations for journal submission

Funding: To be completed by authors.

Competing interests: To be completed by authors, including any BSP training, certification, practice, or organizational affiliations.

Ethics approval and consent to participate: Not applicable to this narrative review.

Data availability: Not applicable.

Author contributions and acknowledgments: To be completed by authors.

Selected references

1. Hildebrand A, Grand D, Stemmler M. Brainspotting – the efficacy of a new therapy approach for the treatment of posttraumatic stress disorder in comparison to eye movement desensitization and reprocessing (2017).[4]
2. Hildebrand A, Grand D, Stemmler M. [Preliminary study of the efficacy of Brainspotting for posttraumatic stress disorder] (2013).[3]
3. Palsimon Jr T. The preliminary efficacy and clinical applicability of Brainspotting among Filipino women with severe posttraumatic stress disorder (2022).[6]
4. D’Antoni F. Brainspotting reduces disturbance and increases heart rate variability linked to distressing memories: a pilot study (2021).[7]
5. D’Antoni F, Matiz A, Fabbro F, Crescentini C. Psychotherapeutic techniques for distressing memories: a comparative study between EMDR, Brainspotting, and body scan meditation (2022).[5]
6. Corrigan F, Grand D. Brainspotting: recruiting the midbrain for accessing and healing sensorimotor memories of traumatic activation (2013).[1]
7. Corrigan F, Grand D, Raju R. Brainspotting: sustained attention, spinothalamic tracts, thalamocortical processing, and the healing of adaptive orientation truncated by traumatic experience (2015).[2]
8. Foo M, Himawan KK, Susanto E. The impact of online brain-spotting therapy on brain metabolism and PTSD symptoms of intimate sexual violence victims: a single case study (2025).[9]
9. National Institute for Health and Care Excellence. Post-traumatic stress disorder: recommendations (accessed for current clinical positioning).[10]